Tizanidine Hydrochloride Capsule
Product Images NDC 68788-8478

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 68788-8478). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tizanidine Structure (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 01)

Chemical structure of tizanidine hydrochloride showing a chlorinated bicyclic compound with a thiazole ring and an imidazoline moiety, labeled with HCl for the hydrochloride salt form.*

FDA Label Image

Figure 1 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 02)

A pharmacokinetic line graph depicting plasma tizanidine concentration (ng/mL) over 24 hours post-dosing for 2 x 4 mg tizanidine tablets and capsules under fed and fasting conditions. The graph compares four groups, showing concentration peaks and decline over time after oral administration.*

FDA Label Image

Figure 2 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 03)

A line graph showing improvement in Ashworth Score over time (hours post-dose) for 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The 16 mg group shows the greatest improvement peaking around 2 hours, followed by 8 mg, with placebo showing minimal change.*

FDA Label Image

Figure 3 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 04)

A line graph showing improvement in Ashworth Score over three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The graph compares two groups: tizanidine (mean dose 28.8 mg) with improvement scores consistently below zero, and placebo with scores near zero or slightly above, each with error bars indicating variability.*

FDA Label Image

Image (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 143 1)

FDA Label Image

Tizanidine HCl Capsules 6mg (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 07)

Label for Tizanidine HCl Capsules 6mg, a prescription oral capsule manufactured by Ingenus Pharmaceuticals, LLC and labeled by Preferred Pharmaceuticals, Inc. The label states each capsule contains 6.87 mg tizanidine hydrochloride equivalent to 6 mg tizanidine base. The label includes storage instructions, a barcode, and space for lot, batch, and expiration dates, along with dosing directions in English and Spanish.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.